文献速递外周动脉疾病

紫杉醇涂层器械治疗股腘动脉闭塞性病变后死亡率:随机对照试验更新系统评价与荟萃分析

Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Endovasc Ther · 2021-06-09

该系统评价与荟萃分析纳入34项随机对照试验共7654例股腘动脉闭塞性疾病患者(84%为间歇性跛行),比较紫杉醇涂层器械与非涂层对照的全因死亡率。结果显示两组全因死亡率无显著差异(RR 1.07,95%CI 0.96-1.20,p=0.20),12、24、60个月各时间点死亡率亦均无显著差异。结论认为无证据表明紫杉醇涂层器械增加全因死亡风险,不支持限制其使用或改变监管随访建议。

要点

  • 紫杉醇涂层器械组全因死亡15.0%,非涂层对照组13.5%,RR 1.07(95%CI 0.96-1.20,p=0.20)。
  • 12、24、60个月各时间点全因死亡率组间均无显著差异。
  • 无证据支持限制紫杉醇涂层器械使用或改变监管随访建议。

核心结论

  • 在股腘动脉闭塞性疾病患者中,紫杉醇涂层器械与非涂层器械相比,至60个月各时间点均无全因死亡风险增加的证据。
  • 因此没有理由限制紫杉醇涂层器械的使用,或改变监管机构对该患者人群的随访建议。

研究设计与样本

  • 系统评价与荟萃分析,检索截止2020年12月10日,纳入34项随机对照试验共7654例患者,84%为间歇性跛行。
  • 主要终点为全因死亡率,系统评价注册号CRD42020216140。

主要发现

  • 紫杉醇器械组4147例中622例死亡(15.0%),非涂层对照组3507例中475例死亡(13.5%),RR 1.07(95%CI 0.96-1.20,p=0.20,I2=0%)。
  • 12个月全因死亡率组间相似(34项研究,7654例;RR 0.99,95%CI 0.81-1.22,p=0.94,I2=0%)。
  • 24个月全因死亡率组间相似(20项研究,3799例;RR 1.16,95%CI 0.87-1.55,p=0.31,I2=0%)。
  • 60个月全因死亡率组间相似(9项研究,2288例;RR 1.19,95%CI 0.98-1.45,p=0.08,I2=0%)。

临床怎么用

  • 对于股腘动脉闭塞性疾病,紫杉醇涂层球囊和支架可继续按现有适应证使用,无需因死亡风险顾虑而限制。
  • 监管机构对该患者人群的随访建议无需因本品类器械调整。

局限性

  • 60个月时间点仅纳入9项研究共2288例患者,样本量有限。
  • 84%患者为间歇性跛行,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A late increased mortality risk has been reported in a summary level meta-analysis of patients with femoropopliteal artery occlusive disease treated with paclitaxel-coated angioplasty balloons and stents. However, at the longer follow up timepoints that analysis was limited by small trial numbers and few participants. The aim of this study was to report an updated summary level risk of all-cause mortality after treatment with paclitaxel-coated devices in that same patient group. MATERIALS AND METHODS: We performed a systematic review and meta-analysis of randomized controlled trials to investigate the mortality outcomes associated with paclitaxel-coated devices used to treat patients with occlusive disease of femoropopliteal arteries (last search date December 10, 2020). The single primary endpoint was all-cause mortality. RESULTS: We identified 34 randomized controlled trials (7654 patients; 84% intermittent claudication). There were 622 deaths among 4147 (15.0%) subjects in the paclitaxel device group and 475 deaths among 3507 (13.5%) subjects in the noncoated control group [relative risk ratio (RR) 1.07, 95% confidence interval (CI) 0.96 to 1.20, p=0.20, I2=0%). All-cause mortality was similar between groups at 12 months (34 studies, 7654 patients; RR 0.99, 95% CI 0.81 to 1.22, p=0.94, I2=0%), 24 months (20 studies, 3799 patients; RR 1.16, 95% CI 0.87 to 1.55, p=0.31, I2=0%), and 60 months (9 studies, 2288 patients; RR 1.19, 95% CI 0.98 to 1.45, p=0.08, I2=0%). CONCLUSION: This updated meta-analysis with included additional trials and larger patient numbers shows no evidence of increased risk of all-cause mortality in patients treated with paclitaxel-coated devices, compared with uncoated devices for femoropopliteal disease at all time points to 60 months. There is therefore no justification to limit their use, or alter regulatory body follow-up recommendations in this patient population. SYSTEMATIC REVIEW REGISTRATION: CRD42020216140.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Dinh K, Limmer AM, Chen AZL, et al. Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Endovasc Ther. 2021. PMID: 34106028. doi:10.1177/15266028211023505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。